Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03396445
Title Safety and Pharmacokinetics Study of MK-5890 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp
Indications

Advanced Solid Tumor

Therapies

MK-5890

MK-5890 + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA | ESP


No variant requirements are available.